Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 + atezolizumab in high-risk skin cancers
NCT03901573Phase 2Terminated
- Sponsor
- NeoImmuneTech
- Start
- Dec 2019
- Primary completion
- Aug 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in melanoma, Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (cSCC), sponsored by NeoImmuneTech. Started Dec 2019; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
melanomaMerkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03901573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901573.